An observational study in Hemoptysis, sponsored by Qiu Jipeng. Not yet recruiting. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-21.
Sponsored by Qiu Jipeng · Observational
This is a prospective, multicenter, observational registry study of hemoptysis in China. Hospitalized patients with active hemoptysis who undergo vascular interventional diagnosis and therapy will be consecutively enrolled from tertiary hospitals across China. Baseline clinical, imaging, angiographic, procedural, and in-hospital outcome data will be collected, and patients will be followed at 1 and 3 months and every 6 months for at least 2 years. The study aims to describe the real-world epidemiology and etiology spectrum of hemoptysis in China, evaluate short- and long-term outcomes of interventional therapy, identify independent risk factors for recurrence, and build a recurrence prediction model to support standardized diagnosis and treatment of hemoptysis.
Background: Hemoptysis is one of the most common respiratory emergencies, with a mortality of over 75% for massive hemoptysis when untreated. Bronchial artery embolization and other vascular interventions have become first-line therapy, with immediate hemostasis rates of 70-99%. However, no nationwide standardized multicenter registry for hemoptysis exists in China; the epidemiological characteristics, etiology spectrum, individualized interventional strategies, long-term prognosis, and recurrence mechanisms of Chinese patients with hemoptysis remain unclear.
Objectives: (1) To describe the cross-sectional etiology spectrum and epidemiological characteristics of hemoptysis in China; (2) to evaluate the immediate and long-term efficacy of vascular interventional therapy, including immediate hemostasis success rate, clinical success rate, and long-term recurrence rate across different etiologies; (3) to identify independent risk factors for post-interventional recurrence using Cox regression and construct a nomogram prediction model; (4) to validate the clinical value of the "systemic-to-pulmonary shunt" hypothesis in interventional management of hemoptysis; (5) to provide high-quality evidence for standardization of interventional diagnosis and treatment of hemoptysis.
Methods: Consecutively hospitalized patients aged ≥18 years with active hemoptysis (>100 mL in a single episode or >300 mL/day) refractory to medical treatment, confirmed by chest CT/CTA, bronchoscopy, or angiography, and undergoing vascular interventional diagnosis and therapy will be enrolled. A minimum of 2500 patients will be enrolled over approximately 4 years (September 2026 to December 2030). Follow-up visits are scheduled at 1 and 3 months after discharge and every 6 months thereafter for at least 2 years, recording hemoptysis recurrence, intervention-related complications, all-cause and hemoptysis-specific death.
37 studies on the registry are indexed under Hemoptysis; 6 are open to participants now.
This study's planned enrollment of 2,500 is above the median of 176 across 15 observational studies indexed under Hemoptysis.
Browse Hemoptysis studies →Qiu Jipeng is the lead sponsor of 3 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Hospitalized adults with active hemoptysis undergoing vascular interventional diagnosis and therapy at tertiary hospitals with respiratory interventional capability in China
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Not applicable. This is an observational patient registry. All clinical procedures (including bronchial artery embolization) are part of routine medical care and are not assigned as study interventions by the investigator.
Hemoptysis recurrence within 2 years
Time to and incidence of hemoptysis recurrence (re-bleeding requiring medical attention) within 2 years after enrollment, assessed by telephone or outpatient follow-up every 6 months.
Time frame: Through 2 years after enrollment.
Hemoptysis-specific mortality
Death attributable to hemoptysis (e.g., asphyxia or hemorrhagic shock due to pulmonary bleeding) within 2 years after enrollment.
Time frame: Through 2 years after enrollment.
All-cause mortality
Death from any cause within 2 years after enrollment.
Time frame: Through 2 years after enrollment.
No study locations are listed for this record.
Start is estimated for Oct 2026; primary completion for Dec 2030, 50 months later.
Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Oct 2026, on Oct 15, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Qiu Jipeng